We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Hand-foot syndrome and survival in patients with advanced non-small-cell lung cancer receiving anlotinib: a subgroup analysis of data from the ALTER 0303 study.
- Authors
Nan, Xueli; Xie, Chao; Zhu, Qingqing; Zhang, Jianjun; Fu, Shuai; Han, Xiao; Zhang, Qiujing; Han, Baohui; Liu, Jie
- Abstract
Background: The ALTER 0303 study showed that anlotinib can significantly improve overall survival (OS) compared with the placebo in advanced non-small-cell lung cancer (NSCLC). Hand-foot syndrome (HFS) is a common anlotinib-related adverse event. The aim of this study was to assess the association of HFS with clinical benefit. Methods: A subgroup analysis of patients treated with anlotinib from the ALTER 0303 study was performed. Our analysis assessed if the appearance of anlotinib-related HFS in the first 42 days (second-cycle HFS) and at any time could produce better clinical benefits. Results: In this study, 294 patients were treated with anlotinib. Of which, 129 patients had HFS at any time, and 76 patients developed HFS in the first 2 cycles. Patients who received anlotinib and developed HFS had significantly prolonged OS, progression-free survival (PFS) compared to those who did not develop HFS in the first 2 cycles (13.5 vs 8.7 months, p = 0.001; adjusted hazard ratio (HR) 0.63 (95% confidence interval [CI] 0.44–0.89), p = 0.009; 5.8 vs 4.5 months, p = 0.001; adjusted HR, 0.59 [0.43–0.81], p = 0.001). The significant OS and PFS benefits for patients with HFS versus without were seen at any time (14.5 vs 7.3 months, p = 0.000; adjusted HR, 0.50 [0.36–0.67], p = 0.000; 5.8 vs 4.2 months, p = 0.000; adjusted HR, 0.49 [0.37–0.65], p = 0.000). In addition, the grade of severity of HFS was strongly correlated with OS (p = 0.000). Conclusion: Presence of HFS may be a potential clinical marker for the treatment of NSCLC with anlotinib.
- Subjects
NON-small-cell lung carcinoma; HAND-foot syndrome; DATA analysis; SUBGROUP analysis (Experimental design); BIOMARKERS
- Publication
International Journal of Clinical Oncology, 2020, Vol 25, Issue 8, p1492
- ISSN
1341-9625
- Publication type
Article
- DOI
10.1007/s10147-020-01683-0